Alvotech (ALVO) Posts Q3 Loss and Falls Short of Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy ALVO?
Source: NASDAQ.COM
Earnings Performance: Alvotech reported a quarterly loss of $0.02 per share, missing the Zacks Consensus Estimate of $0.05, and showing a significant decline from earnings of $0.19 per share a year ago.
Revenue Insights: The company generated revenues of $113.86 million, falling short of the Zacks Consensus Estimate by 11.6%, but still showing growth compared to $102.99 million in the same quarter last year.
Stock Outlook: Alvotech's stock has underperformed, losing about 57.8% since the start of the year, and currently holds a Zacks Rank #4 (Sell), indicating expectations of further underperformance in the near future.
Industry Context: The Medical - Biomedical and Genetics industry, to which Alvotech belongs, is currently ranked in the top 34% of Zacks industries, suggesting potential for better performance compared to lower-ranked sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 4.710
Low
5.00
Averages
8.75
High
10.00
Current: 4.710
Low
5.00
Averages
8.75
High
10.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alvotech Increases Share Capital by $125,000
- Share Capital Increase: Alvotech successfully raised its share capital by $125,000 through the issuance of 12.5 million ordinary shares, enhancing its capital structure to support future growth.
- Subsidiary Shareholding: Alvotech Manco ehf. subscribed to all newly issued shares at $5.2 per share, holding 4.7% of the company, reflecting confidence in Alvotech's future prospects.
- Stable Outstanding Shares: While total issued shares increased from 334,038,147 to 346,538,147, the number of outstanding shares remains unchanged at 330,284,142, ensuring market stability.
- Purpose of Equity Financing: The share issuance aims to replenish the treasury shares reduced due to the lending of ordinary shares, ensuring the company can meet its financial obligations and enhancing financial flexibility.
See More
Alvotech Under Investigation Following 34% Stock Drop After FDA CRL
- Stock Price Plunge: Alvotech's stock plummeted 34% in a single trading session after receiving a Complete Response Letter (CRL) from the FDA, dropping from $7.65 to $5.03, indicating severe market concerns regarding its manufacturing capabilities and regulatory compliance.
- Regulatory Investigation Launched: Hagens Berman is investigating whether Alvotech misled investors about significant manufacturing failures at its Reykjavik, Iceland facility prior to public disclosure, potentially undermining investor confidence in the company’s future.
- Major Financial Downgrade: The deficiencies cited in the FDA's CRL forced Alvotech to drastically cut its 2025 revenue guidance from $700 million and reduce its adjusted EBITDA outlook by 58%, posing a significant threat to the company's financial health.
- Investor Loss Alert: Hagens Berman is urging all investors who suffered substantial losses in Alvotech to contact them to participate in the investigation and seek potential compensation, reflecting concerns over the company's transparency and governance structure.
See More
Alvotech Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ:ALVO) due to allegations of issuing materially misleading business information, indicating that investors may be entitled to compensation without any upfront costs.
- Significant Stock Drop: Following a press release on November 2, 2025, where Alvotech disclosed that the FDA issued a complete response letter for its Biologics License Application, the stock plummeted 34% on November 3 and nearly 4% on November 4, reflecting market concerns over compliance issues.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, emphasizing the importance of selecting qualified legal counsel with a proven track record in securities litigation to ensure effective representation.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and reputation in the securities litigation space.
See More
Alvotech Faces Securities Claims Investigation by Rosen Law Firm
- Securities Claims Investigation: Rosen Law Firm is investigating Alvotech (NASDAQ: ALVO) for potential securities claims due to allegations of issuing materially misleading business information, which has negatively impacted investor confidence and the company's reputation.
- Stock Price Plunge: Following the November 2, 2025 press release regarding its Biologics License Application, Alvotech's stock price plummeted 34% on November 3 and nearly 4% on November 4, indicating significant market concerns about its future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action to recover losses for investors, with no out-of-pocket fees required, which may encourage more affected shareholders to participate in the legal proceedings.
- Law Firm's Strength: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Alvotech's AVT80 Biosimilar Study Achieves Success
- Clinical Trial Success: Alvotech's AVT80 biosimilar achieved primary endpoints in the AVT80-GL-P01 trial, demonstrating pharmacokinetic similarity to Takeda's Entyvio, which is expected to enhance its competitiveness in the bowel disease treatment market.
- Significant Market Potential: With Entyvio generating $6.4 billion in global net revenue last year, Alvotech's success could capture substantial market share, especially as biosimilars gain increasing attention in the pharmaceutical landscape.
- Positive Regulatory Feedback: Regulatory feedback indicates that the AVT80-GL-P01 trial results meet expectations, confirming pharmacokinetic similarity for AVT80 and AVT16 in subcutaneous and intravenous administration, laying a solid foundation for future market applications.
- Positive Stock Reaction: Following the announcement, Alvotech shares spiked approximately 3% in premarket trading, reflecting investor optimism regarding the biosimilar's prospects, which may further drive the company's financing and expansion plans.
See More
Alvotech Reports Positive Results for AVT80 Study
- Positive Study Results: Alvotech announced that its biosimilar AVT80 met all primary endpoints in clinical trials, demonstrating good safety and tolerability, paving the way for regulatory submissions.
- Strong Market Reaction: Following the announcement of positive pharmacokinetic study results, Alvotech's shares surged nearly 10% in pre-market trading on Thursday, reflecting investor optimism about the biosimilar's prospects.
- Significant Market Potential: With Entyvio's projected global net revenue of $6.4 billion in 2025, Alvotech's AVT80, if successfully launched, stands to capture a substantial share of this lucrative market.
- Extensive Industry Partnerships: Alvotech has established collaborations with multiple global pharmaceutical companies, including Teva and Cipla, showcasing its strong network and influence in the biosimilar market.
See More
Alvotech Increases Share Capital by $125,000
- Share Capital Increase: Alvotech successfully raised its share capital by $125,000 through the issuance of 12.5 million ordinary shares, enhancing its capital structure to support future growth.
- Subsidiary Shareholding: Alvotech Manco ehf. subscribed to all newly issued shares at $5.2 per share, holding 4.7% of the company, reflecting confidence in Alvotech's future prospects.
- Stable Outstanding Shares: While total issued shares increased from 334,038,147 to 346,538,147, the number of outstanding shares remains unchanged at 330,284,142, ensuring market stability.
- Purpose of Equity Financing: The share issuance aims to replenish the treasury shares reduced due to the lending of ordinary shares, ensuring the company can meet its financial obligations and enhancing financial flexibility.
See More
Alvotech Under Investigation Following 34% Stock Drop After FDA CRL
- Stock Price Plunge: Alvotech's stock plummeted 34% in a single trading session after receiving a Complete Response Letter (CRL) from the FDA, dropping from $7.65 to $5.03, indicating severe market concerns regarding its manufacturing capabilities and regulatory compliance.
- Regulatory Investigation Launched: Hagens Berman is investigating whether Alvotech misled investors about significant manufacturing failures at its Reykjavik, Iceland facility prior to public disclosure, potentially undermining investor confidence in the company’s future.
- Major Financial Downgrade: The deficiencies cited in the FDA's CRL forced Alvotech to drastically cut its 2025 revenue guidance from $700 million and reduce its adjusted EBITDA outlook by 58%, posing a significant threat to the company's financial health.
- Investor Loss Alert: Hagens Berman is urging all investors who suffered substantial losses in Alvotech to contact them to participate in the investigation and seek potential compensation, reflecting concerns over the company's transparency and governance structure.
See More
Alvotech Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ:ALVO) due to allegations of issuing materially misleading business information, indicating that investors may be entitled to compensation without any upfront costs.
- Significant Stock Drop: Following a press release on November 2, 2025, where Alvotech disclosed that the FDA issued a complete response letter for its Biologics License Application, the stock plummeted 34% on November 3 and nearly 4% on November 4, reflecting market concerns over compliance issues.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, emphasizing the importance of selecting qualified legal counsel with a proven track record in securities litigation to ensure effective representation.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and reputation in the securities litigation space.
See More
Alvotech Faces Securities Claims Investigation by Rosen Law Firm
- Securities Claims Investigation: Rosen Law Firm is investigating Alvotech (NASDAQ: ALVO) for potential securities claims due to allegations of issuing materially misleading business information, which has negatively impacted investor confidence and the company's reputation.
- Stock Price Plunge: Following the November 2, 2025 press release regarding its Biologics License Application, Alvotech's stock price plummeted 34% on November 3 and nearly 4% on November 4, indicating significant market concerns about its future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action to recover losses for investors, with no out-of-pocket fees required, which may encourage more affected shareholders to participate in the legal proceedings.
- Law Firm's Strength: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Alvotech's AVT80 Biosimilar Study Achieves Success
- Clinical Trial Success: Alvotech's AVT80 biosimilar achieved primary endpoints in the AVT80-GL-P01 trial, demonstrating pharmacokinetic similarity to Takeda's Entyvio, which is expected to enhance its competitiveness in the bowel disease treatment market.
- Significant Market Potential: With Entyvio generating $6.4 billion in global net revenue last year, Alvotech's success could capture substantial market share, especially as biosimilars gain increasing attention in the pharmaceutical landscape.
- Positive Regulatory Feedback: Regulatory feedback indicates that the AVT80-GL-P01 trial results meet expectations, confirming pharmacokinetic similarity for AVT80 and AVT16 in subcutaneous and intravenous administration, laying a solid foundation for future market applications.
- Positive Stock Reaction: Following the announcement, Alvotech shares spiked approximately 3% in premarket trading, reflecting investor optimism regarding the biosimilar's prospects, which may further drive the company's financing and expansion plans.
See More
Alvotech Reports Positive Results for AVT80 Study
- Positive Study Results: Alvotech announced that its biosimilar AVT80 met all primary endpoints in clinical trials, demonstrating good safety and tolerability, paving the way for regulatory submissions.
- Strong Market Reaction: Following the announcement of positive pharmacokinetic study results, Alvotech's shares surged nearly 10% in pre-market trading on Thursday, reflecting investor optimism about the biosimilar's prospects.
- Significant Market Potential: With Entyvio's projected global net revenue of $6.4 billion in 2025, Alvotech's AVT80, if successfully launched, stands to capture a substantial share of this lucrative market.
- Extensive Industry Partnerships: Alvotech has established collaborations with multiple global pharmaceutical companies, including Teva and Cipla, showcasing its strong network and influence in the biosimilar market.
See More
